Potential drug-drug interactions in paediatric outpatient prescriptions in Nigeria and implications for the future

Kazeem Adeola Oshikoya, Ibrahim Adekunle Oreagba, Brian Godman, Fisayo Solomon Oguntayo, Joseph Fadare, Samuel Orubu, Amos Massele, Idowu Odunayo Senbanjo

Research output: Contribution to journalArticle

5 Citations (Scopus)
28 Downloads (Pure)


BACKGROUND: Information regarding the incidence of drug-drug interactions (DDIs) and adverse drug events (ADEs) among paediatric patients in Nigeria is limited.

METHODS: Prospective clinical audit among paediatric outpatients in four general hospitals in Nigeria over a 3-month period. Details of ADEs documented in case files was extracted.

RESULTS: Among 1233 eligible patients, 208 (16.9%) received prescriptions with at least one potential DDI. Seven drug classes were implicated with antimalarial combination therapies predominating. Exposure mostly to a single potential DDI, commonly involved promethazine, artemether/lumefantrine, ciprofloxacin and artemether/lumefantrine. Exposure mostly to major and serious, and moderate and clinically significant, potential DDIs. Overall exposure similar across all age groups and across genders. A significant association was seen between severity of potential DDIs and age. Only 48 (23.1%) of these patients presented at follow-up clinics with only 15 reporting ADEs.

CONCLUSION: There was exposure to potential DDIs in this population. However, potential DDIs were associated with only a few reported ADEs.

Original languageEnglish
Pages (from-to)1505-1515
Number of pages11
JournalExpert Review of Clinical Pharmacology
Issue number11
Publication statusPublished - 21 Sep 2016


  • drug interactions
  • pediatrics
  • Nigeria
  • adverse drug events
  • clinical audit

Cite this